X4 Pharmaceuticals Announces New Employee Inducement Awards
X4 Pharmaceuticals, a leader in developing therapies for rare immune diseases, has taken a significant step in enhancing its workforce. Effective May 30, the company revealed the grant of inducement awards to new team members under its 2019 Inducement Equity Incentive Plan. This move aligns with their goal of recruiting top talent while staying compliant with Nasdaq Listing Rule 5635(c)(4).
Inducement Award Details
The recent inducement awards include options to purchase a total of 5,545 shares of common stock from X4. These options come with a ten-year term and have an exercise price set at $3.40 per share, which directly corresponds to the stock's closing price on the date of the grant. The vesting schedule for these options is particularly structured: 25% of the shares will vest after one year, with the remaining shares vesting monthly over the subsequent 36 months. This structure emphasizes the company's focus on long-term commitment from its employees as they navigate their careers at X4.
The 2019 Inducement Equity Incentive Plan
The 2019 Inducement Plan is designed exclusively for granting equity awards to individuals not previously employed by X4. This strategic framework not only incentivizes new employees but also reflects the company's commitment to fostering a motivated and aligned workforce that shares its vision for patient care.
About X4 Pharmaceuticals
X4 is dedicated to advancing the lives of patients with rare immune conditions by developing innovative treatments. Their flagship therapy, mavorixafor, is designed as an orally available antagonist of the CXCR4 receptor. Currently, mavorixafor is marketed in the United States under the brand name XOLREMDI. This groundbreaking medication targets specific immune disorders and addresses significant unmet medical needs.
Ongoing Clinical Trials
In addition to its current product offerings, X4 is also engaged in ongoing clinical trials aimed at expanding mavorixafor's applications. Notably, the company is conducting a pivotal Phase 3 clinical trial named 4WARD, focusing on chronic neutropenic disorders. This commitment to rigorous research ensures that X4 Pharmaceuticals is at the forefront of innovation.
Company Location and Future Aspirations
Headquartered in Boston, X4 Pharmaceuticals aims to build upon its successes and continue servicing patients who suffer from rare diseases. Their proactive approach to therapy development and commitment to clinical excellence ensures that they remain a key player in the field of immunology.
Investor Relations
X4 Pharmaceuticals prioritizes communication with its investors. Daniel Ferry, the Managing Director at LifeSci Advisors, is available for inquiries. Investors can reach him directly via email at daniel@lifesciadvisors.com or by phone at (617) 430-7576.
Frequently Asked Questions
What are the inducement awards issued by X4 Pharmaceuticals?
The inducement awards are options to purchase 5,545 shares of common stock aimed at attracting new employees under the company's 2019 Inducement Plan.
What is the exercise price for the options issued?
The exercise price for the options is set at $3.40 per share, which matches the closing price on the grant date.
What does the vesting schedule look like for these options?
Options will vest over four years, with 25% vesting after 12 months, and the rest vesting monthly over the next three years.
What is mavorixafor?
Mavorixafor is an orally available CXCR4 antagonist used to treat certain rare diseases and marketed as XOLREMDI in the U.S.
How can I get in touch with X4 Pharmaceuticals' investor relations?
Daniel Ferry is the point of contact for investor relations at X4, and he can be reached at daniel@lifesciadvisors.com or (617) 430-7576.
